Edgewise Therapeutics (EWTX) director Fox received 728 shares
Stocks in this Quantisnow insightHealth Care
Insider transactions reported
Jonathan C Fox (director at Edgewise Therapeutics Inc., EWTX) reported that they received 728 shares on Oct 1, 2025. After these transactions the filing shows 13,002 shares held directly.
- Reporting person
- Fox Jonathan C
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Oct 1, 2025 | Grant or award (A) | Common Stock1 | +728 | - | - | 13,002 direct |
Holdings before and after
- Common Stock: 12,274 to 13,002 direct
Footnotes from the filing
- 1. Consists of restricted stock units, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. (the Issuer ) common stock, granted and released to the reporting person on October 1, 2025, as a Quarterly Retainer Award pursuant to Section 2.4 of the Issuer's Outside Director Compensation Policy, as amended.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Fox report in this EWTX Form 4?
Jonathan C Fox (director at Edgewise Therapeutics Inc., EWTX) reported that they received 728 shares on Oct 1, 2025. After these transactions the filing shows 13,002 shares held directly.
How many EWTX shares does Fox hold after this filing?
The filing shows 13,002 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for EWTX
Earlier insider filings at EWTX
- Aug 28, 2025Chief Scientific Officer Russell Alan J exercised 100,000 shares at a strike of $0.18 and sold $1,459,760 worth of shares (100,000 units at $14.60) (SEC Form 4)
- Aug 14, 2025SEC Form 4 filed by Chief Development Officer Blaustein Robert
- Aug 14, 2025General Counsel Moore John R converted options into 5,781 shares and sold $28,097 worth of shares (2,098 units at $13.39), increasing direct ownership by 56% to 10,214 units (SEC Form 4)
- Aug 14, 2025Chief Business Officer Derakhshan Behrad converted options into 5,781 shares and sold $33,360 worth of shares (2,491 units at $13.39), increasing direct ownership by 16% to 23,645 units (SEC Form 4)
- Aug 14, 2025Chief Financial Officer Carruthers R Michael converted options into 5,781 shares and sold $19,124 worth of shares (1,428 units at $13.39), increasing direct ownership by 5% to 86,162 units (SEC Form 4)
Keep researching EWTX
- EWTX insider tradesEvery buy and sale reported by Edgewise Therapeutics Inc. officers, directors and large holders.
- What is Form 4?The SEC filing that reports a change in an insider's holdings, such as a purchase, sale, option exercise or grant, generally within two business days.
- Form 4 explainedForm 4 is the SEC filing that discloses when officers, directors and 10% owners buy or sell company stock, due within 2 business days. Learn every key field and code.
- Insider trading trackerThe latest insider buys and sales across every stock.
- EWTX earnings historyPast Edgewise Therapeutics Inc. earnings releases, newest first.
- EWTX financial statementsRevenue, profit, cash flow and balance sheet from Edgewise Therapeutics Inc.'s SEC filings.
Quantisnow market dataNASDAQ
EWTX
Edgewise Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2021
Get push alerts for EWTX
Full EWTX profile on Quantisnow Follow EWTX and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time